On ECHEMI
Home > Drugs > Esophageal cancer
Esophageal cancer
Esophageal cancer is a common malignant tumor in humans, accounting for 2% of all malignant tumors and more than 90% of esophageal tumors. It ranks second only to gastric cancer in the retrospective survey of all malignant tumor deaths. It is estimated that about 200,000 people die from esophageal cancer every year in the world. my country is a high-incidence area of esophageal cancer, which is one of the most common malignant tumors that poses a great threat to people's lives and health. The age of onset is mostly over 40 years old, and there are more males than females. However, in recent years, there has been an increasing trend in the number of patients under 40 years old. The occurrence of esophageal cancer is related to chronic stimulation of nitrosamines, inflammation and trauma, genetic factors, and the content of trace elements in drinking water, food and vegetables. However, the exact cause is not clear and needs to be studied.
Related Drugs
Xiao Cancer Tablets
Manufacturer:

Shaanxi Jingfeng Pharmaceutical Co., Ltd.

Xiao Cancer Tablets
Manufacturer:

Shaanxi Jingfeng Pharmaceutical Co., Ltd.

Xiao Cancer Tablets
Manufacturer:

Shenyang Shenlong Pharmaceutical Co., Ltd.

Xiao Cancer Tablets
Manufacturer:

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

Xiao Cancer Tablets
Manufacturer:

Huichuntang Pharmaceutical Co., Ltd.

Xiao Cancer Tablets
Manufacturer:

Yantai Dongcheng Dayang Pharmaceutical Co., Ltd.

Xiao Cancer Tablets
Manufacturer:

Shaanxi Junbisha Pharmaceutical Co., Ltd.

Xiao Cancer Tablets
Manufacturer:

Jilin PROVINCE Tonghua Zhenguo Pharmaceutical Co., Ltd.

Xiao Cancer Tablets
Manufacturer:

Jilin PROVINCE Tonghua Zhenguo Pharmaceutical Co., Ltd.

OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy_injection, solution
Indication: OPDIVO QVANTIG is a combination of nivolumab (a PD-1 blocking antibody) and hyaluronidase indicated for the treatment of multiple cancers, including renal cell carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, used as monotherapy or in combination with chemotherapy or targeted agents in first-line, neoadjuvant, adjuvant, and previously treated settings, with certain indications requiring specific biomarker status, prior therapies, or being approved under accelerated approval based on response rate and duration.
Manufacturer:

E.R. Squibb & Sons, L.L.C.

Related Ingredients
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.